WO2008016643A2 - Entités chimiques, compositions et méthodes - Google Patents

Entités chimiques, compositions et méthodes Download PDF

Info

Publication number
WO2008016643A2
WO2008016643A2 PCT/US2007/017186 US2007017186W WO2008016643A2 WO 2008016643 A2 WO2008016643 A2 WO 2008016643A2 US 2007017186 W US2007017186 W US 2007017186W WO 2008016643 A2 WO2008016643 A2 WO 2008016643A2
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
ethyl
methyl
amino
pyridin
Prior art date
Application number
PCT/US2007/017186
Other languages
English (en)
Other versions
WO2008016643A3 (fr
Inventor
Pu-Ping Lu
Xiangping Qian
Jeffrey T. Finer
Chihyan Chuang (Grace)
Bradley P. Morgan
David J. Morgans, Jr.
Original Assignee
Cytokinetics, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics, Incorporated filed Critical Cytokinetics, Incorporated
Publication of WO2008016643A2 publication Critical patent/WO2008016643A2/fr
Publication of WO2008016643A3 publication Critical patent/WO2008016643A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne des entités chimiques modulant la myosine des muscles lisses et/ou la myosine non musculaire, ainsi que des entités chimiques, des compositions pharmaceutiques et des méthodes de traitement de maladies et de pathologies associées à la myosine des muscles lisses et/ou à la myosine non musculaire.
PCT/US2007/017186 2006-08-01 2007-07-31 Entités chimiques, compositions et méthodes WO2008016643A2 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US83501006P 2006-08-01 2006-08-01
US83490306P 2006-08-01 2006-08-01
US83490406P 2006-08-01 2006-08-01
US83518306P 2006-08-01 2006-08-01
US83490106P 2006-08-01 2006-08-01
US60/835,183 2006-08-01
US60/834,903 2006-08-01
US60/834,904 2006-08-01
US60/835,010 2006-08-01
US60/834,901 2006-08-01
US83523606P 2006-08-02 2006-08-02
US60/835,236 2006-08-02

Publications (2)

Publication Number Publication Date
WO2008016643A2 true WO2008016643A2 (fr) 2008-02-07
WO2008016643A3 WO2008016643A3 (fr) 2008-06-19

Family

ID=38997696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/017186 WO2008016643A2 (fr) 2006-08-01 2007-07-31 Entités chimiques, compositions et méthodes

Country Status (4)

Country Link
AR (1) AR062176A1 (fr)
PE (1) PE20080432A1 (fr)
TW (1) TW200823188A (fr)
WO (1) WO2008016643A2 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009051112A1 (fr) * 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited Composés amides et leur utilisation
US7919511B2 (en) 2006-08-01 2011-04-05 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2011042797A1 (fr) * 2009-10-08 2011-04-14 Icozen Therapeutics Pvt. Ltd. Dérivés de pyrazole en tant que modulateurs du canal calcique activé par la libération du calcium
US7932270B2 (en) 2006-08-01 2011-04-26 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7939548B2 (en) 2006-08-02 2011-05-10 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7939534B2 (en) 2006-08-01 2011-05-10 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
JP2013506715A (ja) * 2009-10-06 2013-02-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｄｋ１インヒビターとして有用な複素環式化合物
US8586751B2 (en) 2009-06-12 2013-11-19 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
WO2015010832A1 (fr) * 2013-07-22 2015-01-29 Syngenta Participations Ag Dérivés hétérocycliques microbiocides
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
WO2016039448A1 (fr) * 2014-09-12 2016-03-17 田辺三菱製薬株式会社 Composé aromatique d'amide d'acide carboxylique
US9458110B2 (en) 2013-02-28 2016-10-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10336762B2 (en) 2017-02-16 2019-07-02 Gilead Sciences, Inc. Pyrrolo[1,2-b]pyridazine derivatives
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
CN111393376A (zh) * 2020-05-11 2020-07-10 安徽赛迪生物科技有限公司 一种2-氯嘧啶-4-甲酸的合成方法
US10875866B2 (en) 2018-07-13 2020-12-29 Gilead Sciences, Inc. Pyrrolo[1,2-B]pyridazine derivatives
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
WO2021092322A1 (fr) * 2019-11-06 2021-05-14 Remedy Plan, Inc. Traitements anticancéreux ciblant des cellules souches cancéreuses
EP3868749A1 (fr) 2016-03-23 2021-08-25 Syngenta Participations Ag Composés herbicides
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140853A (en) * 1975-04-18 1979-02-20 Schering Aktiengesellschaft Process for the preparation of aminopyridines
WO2005108391A1 (fr) * 2004-04-22 2005-11-17 Eli Lilly And Company Amides en tant qu'inhibiteurs de la bace

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140853A (en) * 1975-04-18 1979-02-20 Schering Aktiengesellschaft Process for the preparation of aminopyridines
WO2005108391A1 (fr) * 2004-04-22 2005-11-17 Eli Lilly And Company Amides en tant qu'inhibiteurs de la bace

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919511B2 (en) 2006-08-01 2011-04-05 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7939534B2 (en) 2006-08-01 2011-05-10 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7932270B2 (en) 2006-08-01 2011-04-26 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7939548B2 (en) 2006-08-02 2011-05-10 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2009051112A1 (fr) * 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited Composés amides et leur utilisation
US8329691B2 (en) 2007-10-15 2012-12-11 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
US8586751B2 (en) 2009-06-12 2013-11-19 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
US10030016B2 (en) 2009-10-06 2018-07-24 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as PDK1 inhibitors
US9546165B2 (en) 2009-10-06 2017-01-17 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as PDK1 inhibitors
JP2013506715A (ja) * 2009-10-06 2013-02-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｄｋ１インヒビターとして有用な複素環式化合物
US10668051B2 (en) 2009-10-08 2020-06-02 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
CN104788430B (zh) * 2009-10-08 2019-10-22 理森制药股份公司 吡唑衍生物钙释放激活钙通道调节剂及非小细胞肺癌的治疗方法
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
CN104788430A (zh) * 2009-10-08 2015-07-22 理森制药股份公司 吡唑衍生物钙释放激活钙通道调节剂及非小细胞肺癌的治疗方法
WO2011042797A1 (fr) * 2009-10-08 2011-04-14 Icozen Therapeutics Pvt. Ltd. Dérivés de pyrazole en tant que modulateurs du canal calcique activé par la libération du calcium
CN102834382B (zh) * 2009-10-08 2016-08-03 理森制药股份公司 作为钙释放激活钙通道调节剂的吡唑衍生物
US10246450B2 (en) 2009-10-08 2019-04-02 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
EA024630B1 (ru) * 2009-10-08 2016-10-31 Ризен Фармасьютикалз С.А. Производные пиразола как ингибиторы ионных каналов, активируемых высвобождением кальция (crac)
US8921364B2 (en) 2009-10-08 2014-12-30 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US9758514B2 (en) 2009-10-08 2017-09-12 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US10174034B2 (en) 2009-10-08 2019-01-08 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US9944631B2 (en) 2009-10-08 2018-04-17 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
CN110627724A (zh) * 2009-10-08 2019-12-31 理森制药股份公司 吡唑衍生物钙释放激活钙通道调节剂及非小细胞肺癌的治疗方法
CN102834382A (zh) * 2009-10-08 2012-12-19 理森制药股份公司 作为钙释放激活钙通道调节剂的吡唑衍生物
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9458110B2 (en) 2013-02-28 2016-10-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
WO2015010832A1 (fr) * 2013-07-22 2015-01-29 Syngenta Participations Ag Dérivés hétérocycliques microbiocides
WO2016039448A1 (fr) * 2014-09-12 2016-03-17 田辺三菱製薬株式会社 Composé aromatique d'amide d'acide carboxylique
US11858939B2 (en) 2015-07-06 2024-01-02 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
EP3868749A1 (fr) 2016-03-23 2021-08-25 Syngenta Participations Ag Composés herbicides
US11225479B2 (en) 2017-01-11 2022-01-18 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US10519149B2 (en) 2017-01-11 2019-12-31 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10696673B2 (en) 2017-01-11 2020-06-30 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10793567B2 (en) 2017-01-11 2020-10-06 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11286256B2 (en) 2017-01-11 2022-03-29 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US10336762B2 (en) 2017-02-16 2019-07-02 Gilead Sciences, Inc. Pyrrolo[1,2-b]pyridazine derivatives
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11912702B2 (en) 2017-08-07 2024-02-27 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11535622B2 (en) 2018-07-13 2022-12-27 Gilead Sciences, Inc. Pyrrolo[1,2-b] pyridazine derivatives
US10875866B2 (en) 2018-07-13 2020-12-29 Gilead Sciences, Inc. Pyrrolo[1,2-B]pyridazine derivatives
WO2021092322A1 (fr) * 2019-11-06 2021-05-14 Remedy Plan, Inc. Traitements anticancéreux ciblant des cellules souches cancéreuses
CN114929672A (zh) * 2019-11-06 2022-08-19 治疗方案股份有限公司 靶向癌症干细胞的癌症治疗
CN111393376B (zh) * 2020-05-11 2022-05-13 安徽赛迪生物科技有限公司 一种2-氯嘧啶-4-甲酸的合成方法
CN111393376A (zh) * 2020-05-11 2020-07-10 安徽赛迪生物科技有限公司 一种2-氯嘧啶-4-甲酸的合成方法

Also Published As

Publication number Publication date
TW200823188A (en) 2008-06-01
WO2008016643A3 (fr) 2008-06-19
AR062176A1 (es) 2008-10-22
PE20080432A1 (es) 2008-05-29

Similar Documents

Publication Publication Date Title
WO2008016643A2 (fr) Entités chimiques, compositions et méthodes
EP0783500B1 (fr) Derives aminoheterocycliques en tant qu'agents antithrombotiques ou anticoagulants
AU2006282456B2 (en) Novel pyridine derivative and pyrimidine derivative (3)
US7939534B2 (en) Certain chemical entities, compositions, and methods
JP6759100B2 (ja) 治療用阻害化合物
EP1831198B1 (fr) Dérivés de pyridinecarboxamide employés en tant qu'agents anticancéreux
CA2736955C (fr) Composes multiheteroaryles servant d'inhibiteurs de la h-pgds, ainsi que leur utilisation dans le traitement des maladies induites par la prostaglandine d2
KR101546595B1 (ko) 헤테로아릴메틸 아마이드
TW200306180A (en) New compounds
NZ576501A (en) Pyridine carboxamides as 11-beta-hsd1 inhibitors
WO2008025798A1 (fr) Composés de pyridine permettant de traiter les troubles liés à gpr119
IL210843A (en) Certain quinorainin-3 – monooxygenase traces, and pharmaceuticals containing them
AU2010291212A1 (en) Heteroaryl compounds as kinase inhibitors
US7939548B2 (en) Certain chemical entities, compositions, and methods
WO2005063743A1 (fr) Dérivé de thiazole
WO2009023193A1 (fr) Entités chimiques particulières, compositions, et procédés
US7932270B2 (en) Certain chemical entities, compositions, and methods
JP2009501216A (ja) 新規なピリジン類縁体
CA2551604A1 (fr) Derive d'amidopyrazole
US7919511B2 (en) Certain chemical entities, compositions, and methods
WO2008016676A2 (fr) Entités chimiques, compositions et méthodes
WO2008016666A2 (fr) Entités chimiques, compositions et méthodes
JP7386576B2 (ja) Ｎ－（１ｈ－イミダゾール－２－イル）ベンズアミド化合物および該化合物を活性成分として含む医薬組成物
US20090198057A1 (en) Certain Chemical Entities, Compositions, and Methods
AU2013213705A1 (en) Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836402

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07836402

Country of ref document: EP

Kind code of ref document: A2